InDex Pharmaceuticals AB

CEO:  Peter Zerhouniindex_logo_


Despite the currently available drug treatment alternatives, a large group of patients with ulcerative colitis suffer from severe symptoms such as pain and frequent, bloody diarrhea. The only remaining option for many of these patients is to undergo colectomy.

InDex Pharmaceuticals develops Kappaproct – a completely new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based immunomodulatory sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

The European marketing rights for Kappaproct have been out-licensed to Almirall S.A. in an agreement that could potentially bring InDex milestones in excess of 100 million euro, as well as well as double-digit royalties.

Share Button